1cBio Licenses PARP1 Inhibitor OC-3 to Lee’s Pharm in $27 Million Asia Deal
1cBio has struck a regional licensing deal with Hong Kong-based Lee’s Pharmaceutical Holdings to advance OC-3, its next-generation selective PARP1 inhibitor, across Greater China and parts of Southeast Asia. Under the agreement announced September 9,…